173 related articles for article (PubMed ID: 25026207)
1. RhoA mutations identified in diffuse gastric cancer.
Zhou J; Hayakawa Y; Wang TC; Bass AJ
Cancer Cell; 2014 Jul; 26(1):9-11. PubMed ID: 25026207
[TBL] [Abstract][Full Text] [Related]
2. c-Met-dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis.
Liu J; Li S; Chen S; Chen S; Geng Q; Xu D
J Pathol; 2019 Sep; 249(1):126-136. PubMed ID: 31056743
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.
Röcken C; Behrens HM; Böger C; Krüger S
J Clin Pathol; 2016 Jan; 69(1):70-5. PubMed ID: 26251521
[TBL] [Abstract][Full Text] [Related]
4. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.
Ushiku T; Ishikawa S; Kakiuchi M; Tanaka A; Katoh H; Aburatani H; Lauwers GY; Fukayama M
Gastric Cancer; 2016 Apr; 19(2):403-411. PubMed ID: 25823974
[TBL] [Abstract][Full Text] [Related]
5. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis.
Cai J; Niu X; Chen Y; Hu Q; Shi G; Wu H; Wang J; Yi J
Neoplasia; 2008 Jan; 10(1):41-51. PubMed ID: 18231637
[TBL] [Abstract][Full Text] [Related]
6. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.
Kakiuchi M; Nishizawa T; Ueda H; Gotoh K; Tanaka A; Hayashi A; Yamamoto S; Tatsuno K; Katoh H; Watanabe Y; Ichimura T; Ushiku T; Funahashi S; Tateishi K; Wada I; Shimizu N; Nomura S; Koike K; Seto Y; Fukayama M; Aburatani H; Ishikawa S
Nat Genet; 2014 Jun; 46(6):583-7. PubMed ID: 24816255
[TBL] [Abstract][Full Text] [Related]
7. Aberrant alternative splicing of RHOA is associated with loss of its expression and activity in diffuse-type gastric carcinoma cells.
Miyamoto S; Nagamura Y; Nakabo A; Okabe A; Yanagihara K; Fukami K; Sakai R; Yamaguchi H
Biochem Biophys Res Commun; 2018 Jan; 495(2):1942-1947. PubMed ID: 29247652
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-Function
Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
[TBL] [Abstract][Full Text] [Related]
9. Genomic and Pathologic Profiling of Very Well-Differentiated Gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation.
Rokutan H; Arai Y; Kunita A; Yamasaki S; Nakamura H; Hama N; Nakayama A; Hosoda F; Totoki Y; Fujishiro M; Seto Y; Shibata T; Ushiku T
Am J Surg Pathol; 2024 Jun; 48(6):652-661. PubMed ID: 38584451
[TBL] [Abstract][Full Text] [Related]
10. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity.
Liu N; Bi F; Pan Y; Sun L; Xue Y; Shi Y; Yao X; Zheng Y; Fan D
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6239-47. PubMed ID: 15448013
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells.
Korourian A; Roudi R; Shariftabrizi A; Madjd Z
Exp Biol Med (Maywood); 2017 Dec; 242(18):1842-1847. PubMed ID: 28836853
[TBL] [Abstract][Full Text] [Related]
12. Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer.
Chang HR; Nam S; Lee J; Kim JH; Jung HR; Park HS; Park S; Ahn YZ; Huh I; Balch C; Ku JL; Powis G; Park T; Jeong JH; Kim YH
Oncotarget; 2016 Dec; 7(49):81435-81451. PubMed ID: 27806312
[TBL] [Abstract][Full Text] [Related]
13. Identification of "regulation of RhoA activity panel" as a prognostic and predictive biomarker for gastric cancer.
Huang W; Zhao S; Zhang C; Li Z; Ge S; Lian B; Feng H; Wang K; Xu R; Ji J; Gao J; Shi W; Shen L
Aging (Albany NY); 2020 Dec; 13(1):714-734. PubMed ID: 33288739
[TBL] [Abstract][Full Text] [Related]
14. Gastrokine 1 inhibits gastric cancer cell migration and invasion by downregulating RhoA expression.
Yoon JH; Choi WS; Kim O; Choi BJ; Nam SW; Lee JY; Park WS
Gastric Cancer; 2017 Mar; 20(2):274-285. PubMed ID: 27250838
[TBL] [Abstract][Full Text] [Related]
15. ARHGAP-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer.
Komatsu M; Ichikawa H; Chiwaki F; Sakamoto H; Komatsuzaki R; Asaumi M; Tsunoyama K; Fukagawa T; Matsushita H; Boku N; Matsusaki K; Takeshita F; Yoshida T; Sasaki H
Oncogene; 2022 Oct; 41(43):4779-4794. PubMed ID: 36127398
[TBL] [Abstract][Full Text] [Related]
16. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway.
Lin MT; Lin BR; Chang CC; Chu CY; Su HJ; Chen ST; Jeng YM; Kuo ML
Int J Cancer; 2007 Jun; 120(12):2600-8. PubMed ID: 17304514
[TBL] [Abstract][Full Text] [Related]
17. Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma.
Chang KK; Cho SJ; Yoon C; Lee JH; Park DJ; Yoon SS
Ann Surg Oncol; 2016 Dec; 23(13):4238-4246. PubMed ID: 27364501
[TBL] [Abstract][Full Text] [Related]
18. RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach.
Hashimoto T; Ogawa R; Tang TY; Yoshida H; Taniguchi H; Katai H; Oda I; Sekine S
Mod Pathol; 2019 Apr; 32(4):568-575. PubMed ID: 30425335
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells.
Yoon C; Cho SJ; Aksoy BA; Park DJ; Schultz N; Ryeom SW; Yoon SS
Clin Cancer Res; 2016 Feb; 22(4):971-83. PubMed ID: 26482039
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of RhoA/ROCK signaling pathway promotes the apoptosis of gastric cancer cells.
Xu XT; Song QB; Yao Y; Ruan P; Tao ZZ
Hepatogastroenterology; 2012; 59(120):2523-6. PubMed ID: 22584506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
